Chlorpromazine is detectable in the milk of some mothers during therapy, but levels appear not to correlate well with the maternal dose or serum level. Some breastfed infants become drowsy during maternal chlorpromazine therapy. Very limited long-term follow-up data indicate no adverse developmental effects when the drug is used alone. A safety scoring system finds chlorpromazine possible to use cautiously during breastfeeding.[1] However, using it in combination with haloperidol can negatively affect development. Monitor the infant for excessive drowsiness during breastfeeding and for developmental milestones, especially if other antipsychotics are used concurrently.
在治疗期间，一些母亲的乳汁中可检测到氯丙嗪，但含量似乎与母亲的剂量或血清水平相关性不佳。在母亲接受氯丙嗪治疗期间，一些母乳喂养的婴儿会变得嗜睡。非常有限的长期随访数据表明，单独使用该药物时无不良发育影响。一个安全评分系统认为，母乳喂养期间可谨慎使用氯丙嗪。[1] 然而，将其与氟哌啶醇联合使用可能会对发育产生负面影响。母乳喂养期间，监测婴儿是否过度嗜睡以及发育里程碑情况，尤其是在同时使用其他抗精神病药物时。
